Navigation Links
Amsterdam Molecular Therapeutics Receives Opinion on Glybera(R) Marketing Authorisation Application
Date:6/23/2011

AMSTERDAM, June 24, 2011 /PRNewswire/ --


 

- Dossier Re-Examination Process Initiated

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that it has received an opinion on its Marketing Authorisation Application (MAA) for Glybera® (alipogene tiparvovec) as a potential therapy for Lipoprotein Lipase Deficiency ("LPLD"). Following a recent meeting with the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP), AMT has been notified that, at this time, Glybera is not approvable.

Subsequent to a review of the CHMP's letter, AMT believes that Glybera can receive a positive opinion subject to generating additional data from existing patients. AMT has therefore decided to ask for a re-examination of the clinical data package.

"From what we know today, despite the disappointment, we believe that there is an indication from the CHMP that Glybera could receive approval and that the current opinion at this time is a reflection of insufficient proof of clinical benefit of Glybera as a result of low patient numbers measured for chylomicron handling for at least 12 months post treatment. The CHMP also indicated that if certain additional data from already treated patients would confirm current results by the end of 2011, an approval may be possible," noted Jörn Aldag, CEO of AMT. "In the dossier, we provided important data showing Glybera is safe and prevents episodes of pancreatitis, the major clinical complication of LPLD. We appreciate the CHMP's responsibility for caution on such an advanced therapy, so we will work diligently to generate more information and, we hope, ensure that Glybera will still reach patients."

Next steps

As part of the MAA, AMT presented data to the CHMP on Glybera showing evidence in reducing the risk of pancreatitis. Also, the company demonstrated a clear signal of patients' ability to b
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharma and Food Thought Leaders Set to Converge in Amsterdam Next April 2011
2. Amsterdam Molecular Therapeutics Reports Promising Data From Cholesterol Lowering Gene Therapy Study
3. PharmacoFore, Inc. Announces Positive Results from a Phase I Clinical Study of Its Hydromorphone Bio-Activated Molecular Delivery™ System, and Upcoming Presentation at the 2011 BIO Business Forum During the Annual BIO International Convention in Was
4. Latest Molecular Diagnostics Technology Aids German Hospital in Management of European E. coli Crisis
5. Data from Clinical Studies of bioTheranostics CancerTYPE ID® and Breast Cancer Index(SM) Molecular Diagnostic Tests Presented at ASCO 2011 Annual Meeting
6. ImaginAb, Inc. Announces Availability of Custom Protein Radiolabeling Services for Molecular Imaging
7. Medco Partners With MolecularMD on Personalized Medicine Program for Chronic Myeloid Leukemia
8. The World Leader in Molecular Breast Imaging to Premiere Largest Detector in the Industry
9. Gen-Probe Files for US Regulatory Clearance of PANTHER™ System, Fully Automated and Integrated Molecular Testing Instrument
10. Latest Clinical Evidence Supports Promising Outlook for Low-Dose Molecular Breast Imaging (MBI)
11. Cepheid Extends Rapid Molecular Diagnostics Leadership with FDA Clearance of Xpert Clostridium difficile/Epi
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Aug. 28, 2014 Levi & Korsinsky announces ... the United States District Court for the District of ... who purchased Galectin Therapeutics Inc. ("Galectin" or the "Company") ... 28, 2014. For more information, click here: ... during the Class Period the Company violated federal securities ...
(Date:8/28/2014)... 28, 2014 Nonin Medical, Inc., the inventor ... medical monitoring, today announced that the Food and Drug ... finger pulse oximeter for use in the ... into a telemedicine hub or kiosk through a USB ... pediatric to adult patients. The Model 3231 received EU ...
(Date:8/28/2014)... Oregon , August 28, 2014 ... Research titled, "DNA diagnostics Market (products, applications, techniques, ... Trends, Opportunities, Growth and Forecast, 2013 - 2020," ... reach $19 billion by 2020 registering a CAGR ... to provide accurate diagnosis and cost effectiveness over ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Galectin Therapeutics Inc. and Its Board of Directors and a Lead Plaintiff Deadline of September 29, 2014 -- GALT 2Nonin Medical Announces FDA Clearance of Nonin Model 3231 USB Pulse Oximeter 2DNA Diagnostics Market is Expected to Reach $19 Billion by 2020 - Allied Market Research 2DNA Diagnostics Market is Expected to Reach $19 Billion by 2020 - Allied Market Research 3
... 2011 Quest Diagnostics Incorporated (NYSE: DGX ... and services, today announced the CE mark and European ... test on the 3M™ Integrated Cycler.  The new test, ... technique to eliminate nucleic-acid sample extraction, a time-consuming process ...
... N.J., Nov. 1, 2011 MedAvante, Inc., the world,s ... of treatments for central nervous system (CNS) disorders, announced ... 2011 Fifty Fastest Growing Companies. NJBIZ, New ... 50 Fastest Growing Companies in celebration of New Jersey,s ...
Cached Medicine Technology:Quest Diagnostics Announces Launch of Simplexa™ Direct Test for Influenza and Respiratory Viruses in Europe 2Quest Diagnostics Announces Launch of Simplexa™ Direct Test for Influenza and Respiratory Viruses in Europe 3MedAvante Is One of NJ's Fastest Growing Companies 2
(Date:8/28/2014)... about the chance of ,overdiagnosis, through the NHS breast ... according to research published in the British Journal ... survey of around 2,200 women, Cancer Research UK scientists ... cent felt they fully understood the information given about ... cancers that would never have gone on to cause ...
(Date:8/28/2014)... Millennium Treatment Group is excited ... month will be a celebration of the positive ... Along with other treatment facilities and mental health ... the word about this national observance. , National ... of treatment and recovery professionals, and has since ...
(Date:8/28/2014)... Millennium Treatment Group has noticed a ... workplace. A recent report from the National Council ... drug abuse is costing employers an estimated $81 billion ... to drugs affect their employers and the company they ... workplace, causing expensive problems for their employers, such as ...
(Date:8/28/2014)... HealthDay Reporter THURSDAY, Aug. 28, 2014 (HealthDay ... symptoms of multiple sclerosis (MS), a new study from Argentina ... D, smoking and Epstein Barr virus infection. Our study shows ... MS patients," said lead researcher Dr. Mauricio Farez, of the ... Multiple sclerosis is a disease of the nervous system that ...
(Date:8/28/2014)... 2014 Testimony began this week ... transvaginal mesh lawsuit ( http://www.transvaginalmeshlawsuithelp.com/ )involving a ... reports. Court documents pending in the U.S. District ... the case was filed on behalf of a ... allegedly due to vaginal mesh complications associated with ...
Breaking Medicine News(10 mins):Health News:Some women still don't underststand 'overdiagnosis' risk in breast screening 2Health News:Millennium Treatment Group Celebrates National Recovery Month 2Health News:Drug Use Causes Problems in the Workplace 2Health News:Could Too Much Salt Harm MS Patients? 2Health News:Could Too Much Salt Harm MS Patients? 3Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 4
... [Brown University] More than 1.4 million Americans live ... million will need long-term care, whether in a nursing ... an at-home health service provider. , At this time ... on Aging has awarded Brown University a major grant ...
... 15 Danny Wright, Chief Executive Officer,of Alliance ... will be featured in an exclusive interview,with ... p.m. EST. The interview,will be posted on ... 16. The interview will cover topics including ...
... The Center for State and,Local Government Excellence ... Public Policy and Social Research (IPPSR) at Michigan ... the state,s unfunded retiree health,care liability. Michigan ... billion. To help policy leaders develop thoughtful solutions, ...
... NovaBay,Pharmaceuticals, Inc. (AMEX & TSX: NBY), a biopharmaceutical ... or prevention of a wide range of bacterial ... quarter ended September 30, 2007. Net loss ... $1.6 million, or,$0.24 per share, as compared to ...
... United States are estimated to already have bone diseases, ... low bone mass, putting them at increased risk for ... Wang, assistant professor of mechanical engineering at the University ... Two of Wang,s aunts have suffered from the insidious ...
... when a naturally occurring hormone in your body turns against ... melatonin is a popular supplement you take to ... his team of researchers may have some answers. ... biology and biochemistry at UH, describes his teams findings in ...
Cached Medicine News:Health News:Brown to create most comprehensive long-term care database 2Health News:Brown to create most comprehensive long-term care database 3Health News:WallSt.net Announces Upcoming Interview With CEO of Alliance HealthCard 2Health News:Center For Excellence to Fund Analysis of Michigan State Retiree Health Care Reforms 2Health News:NovaBay announces third quarter 2007 financial results 2Health News:NovaBay announces third quarter 2007 financial results 3Health News:NovaBay announces third quarter 2007 financial results 4Health News:NovaBay announces third quarter 2007 financial results 5Health News:NovaBay announces third quarter 2007 financial results 6Health News:NovaBay announces third quarter 2007 financial results 7Health News:Bad to the bone: UD research to shed light on osteoporosis 2Health News:Bad to the bone: UD research to shed light on osteoporosis 3Health News:The hormone of darkness: melatonin could hurt memory formation at night 2Health News:The hormone of darkness: melatonin could hurt memory formation at night 3
Intermittent catheter...
Intermittent catheter...
Intermittent catheter...
Diagnostic and laboratory test reference. Get help with test preparation, interpretation, follow-up, and reimbursement....
Medicine Products: